Idaho DUR Committee Meeting Record

Date: October 21, 2010 **Time:** 9:45 a.m. – 2:00 p.m. **Location:** Idaho Medicaid, 3232 Elder Street, Conference Room DW

Moderator: Mark Turner, MD

Committee Members Present: Wayne Baures, R.Ph, Janet Mayo, R.Ph, Suzette Cooper, R.Ph, and Mark Turner, M.D.

Others Present: Tami Eide, PharmD, Jane Gennrich, PharmD, Annette Paul, RPh, William Milne, RPh, Elise Heil, RPh.

Committee Members Absent: Perry Brown, MD, Paul Cady, PharmD, Myrna Olson-Fisher, NP,

AGENDA ITEMS	PRESENTER	OUTCOME/ACTIONS
Committee Business		
➢ *Introductions*	Tami Eide, PharmD., BCPS	
➢ *Approval of Minutes from July, 20 2010 Meeting*	Tami Eide, PharmD., BCPS	Minutes approved.
➢ *Follow-up Studies*	Annette Paul, RPh. and Jane Gennrich, PharmD.	
o *Type II Diabetes Treatment Guidelines: Use of newer agents*		New information was reviewed – 243 letters were sent and 40 responses have been received. The committee reviewed the responses and a representative profile. Ms. Paul reviewed the elements of the RetroDUR profile with the committee.
o *Suboxone/Subutex – Prescribers*		New information was reviewed – 567 letters were sent to prescribers and 92 responses have been received. The committee reviewed the responses and a representative profile. State staff did a follow up of this study by reviewing the profiles for diagnoses. If no diagnosis was listed for opioid dependency, the pharmacist contacted the prescriber's office and requested the specific diagnosis.
o *Narcotic Use – multiple long-acting agents*		New information was reviewed – 28 letters were sent and 17 responses have been received. The committee reviewed the responses and a representative profile.
➢ *Current Interventions* o *Synagis – Follow-up from Implementation of Updated AAP Guidelines*	Tami Eide, PharmD, BCPS, Elise Heil, RPh., Jane Gennrich, PharmD. and Annette Paul, RPh	Information was presented on the impact of the change in guidelines for Synagis in 2009 by the American Academy of Pediatrics. State staff reviewed the charts of 10 infants who would have received Synagis approval under the previous guidelines but did not meet the new guidelines. None of the infants had adverse outcomes. It was also noted that the overall rate of approval of Synagis did not change in the 2009 season when compared with the previous two seasons.

• *Type II Diabetes Treatment Guidelines: Metformin non-adherence*		This study was done as a follow up to the study on use of newer diabetes agents. During the review, issues were noted of non-compliance with metformin and sub-optimal dosages of metformin. 73 prescriber letters were sent and 16 responses have been received. The committee reviewed the responses and two representative profiles.
o *Suboxone/Subutex: Pharmacy Intervention*		Based on the findings of the previous study, a pharmacy intervention was conducted. 92 letters were sent to pharmacies and 9 responses have been received. An information sheet was included with the letter to educate pharmacists on prescriber DEA/X numbers and concomitant use of drugs of potential abuse with Suboxone and Subutex. Program changes were implemented in September 2010. Currently, patients receiving Suboxone or Subutex will not be able to fill prescriptions for other narcotics with-out an override from DHW. A monthly report will be run to identify new patients.
o *Narcotic Use: Multiple short-acting agents and continuous pain treatment without addition of a long-acting agent*		New information was presented – 587 letters were sent to prescribers and 92 responses have been received. The committee reviewed responses and a representative profile. ProDUR interventions, edits and messaging for the previous quarter were presented and discussed. Only severity level 1 interactions are included, and most receive messages only. For the next meeting, the committee will start reviewing the top interventions and responses, reviewing one interaction type per meeting.
➢ *Severity Analysis*	Annette Paul, RPh	Ms. Paul reviewed the severity ranking functionality that Magellan can use as part of the RetroDUR profile production.
➢ *Study Proposals for Next Quarter* o *Atypical Antipsychotics – Use in Children*	Tami Eide, PharmD, BCPS, Annette Paul RPh, Elise Heil, PharmD, Jane Gennrich, PharmD	Use of atypical antipsychotics in children will be reviewed. Profiles will be reviewed for diagnoses that meet the approved use of these products in adults.
o *Invega Sustenna*		Use of injectable atypical antipsychotic adherence to therapy and previous oral therapy adherence will be reviewed.
o *Combination Beta Agonist/Inhaled Glucocorticoids*		Patients who have been on LABA's for longer periods of time will be reviewed as well as those who are receiving high numbers of rescue inhalers.
o *Lidoderm*		Lidoderm use was reviewed. No patients had a diagnosis of post-herpetic neuralgia which is

o *Topical Nonsteroidals*		the only FDA approved indication. This will not be pursued as an intervention for next quarter. It was recommended to PA this drug for FDA approved diagnosis.
o *5HT-3 Receptor Blocker Antiemetics*		Use of topical nonsteroidal products was reviewed. This will not be pursued for next quarter.
➢ *ProDUR Quarterly Report*	Annette Paul, RPh.	The requests and outcome of the requests for prior authorization for 5HT-3 Receptor blockers were reviewed. Magellan will provide information on point of sale denials for comparison with requests as well as comparative data for other TOP$ states who do not prior authorize this drug class. This class will be reviewed next quarter.
➢ *DUR Quarterly Newsletter*	Tami Eide, PharmD., BCPS	Ms. Paul reviewed the ProDUR message numbers from the month of August 2010. She also reviewed the Drug-Drug interaction problem type in more depth. Going forward, a different problem type will be discussed at each meeting to provide the committee with more in depth information about the Magellan ProDUR messaging.
➢ *Adjourn, 2:00 p.m.*	Mark Turner, M.D.	It was suggested that information about the Suboxone studies and the DHW lock-in program be included in the newsletter.